DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications:A Contemporary Experience From UK General Practice

Spanopoulos, Dionysis, Busse, Michael, Webb, Joanne, Tebboth, Abigail, Gollop, Nicholas D. and Marcus, Michael W. (2019) DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications:A Contemporary Experience From UK General Practice. Clinical Therapeutics, 41 (8). pp. 1622-1630. ISSN 0149-2918

[img]
Preview
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (472kB) | Preview

Abstract

Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. This cross-sectional study examines all DPP-4 inhibitor initiations that require dose adjustment and the dose selection using data from UK general practice. Results indicate that 34% of patients taking a nonlinagliptin DPP-4 inhibitor were given a higher dose and 11% a lower dose than specified in the Summary of Product Characteristics. This reinforces the deviation from Summary of Product Characteristics prescription of DPP-4 inhibitors identified in earlier studies despite improvement in compatibility with routine reporting. (C) 2019 The Authors. Published by Elsevier Inc.

Item Type: Article
Uncontrolled Keywords: dose selection,dpp-4 inhibitors,summary of product characteristics,renal impairment,type 2 diabetes mellitus,uk general practice,type-2 diabetes-mellitus,peptidase 4 inhibitors
Depositing User: LivePure Connector
Date Deposited: 06 May 2020 00:07
Last Modified: 06 May 2020 00:07
URI: https://ueaeprints.uea.ac.uk/id/eprint/75038
DOI: 10.1016/j.clinthera.2019.05.010

Actions (login required)

View Item View Item